[The effect of human recombinant erythropoietin on the lipid peroxidation processes and antioxidant protection of the erythrocytes in patients with chronic kidney failure on hemodialysis].
Twenty patients with terminal-stage chronic renal failure (CRF) underwent long-term hemodialysis. Ten of them (group 1) did not receive human erythropoietin (HEP), four patients (group 2) received HEP for 1 month, six patients (group 3) for 12 months. Group 3 patients exhibited a marked increase in Hb, hematocrit, red cell number, while serum Fe was reduced. MDA rose in group 1 by 34% (p < 0.05), in group 2 by 199% (p < 0.05), was normal in group 3. Red cell catalase and glutathione peroxidase activities were normal. The results evidence that 1-month HEP treatment enhances oxidant degradation of erythrocytic membrane lipids. Lipid peroxidation becomes normal to the end of 1-year HEP treatment despite low SOD activity. Application of HEP in CRF patients is advisable to combine with antioxidant modalities to intensify red cell resistance to hemodialysis.
I A
IA
Rud'ko
T S
TS
Balashova
Iu A
IuA
Pokrovskiĭ
V M
VM
Ermolenko
A A
AA
Kubatiev
D000328:Adult; D000975:Antioxidants; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D000975:Antioxidants; D011994:Recombinant Proteins; D004921:Erythropoietin; D008315:Malondialdehyde
Vliianie rekombinantnogo chelovecheskogo éritropoétina na protsessy perekisnogo okisleniia lipidov i antioksidantnuiu zashchitu éritrotsitov bol'nykh khronicheskoĭ pochechnoĭ nedostatochnost'iu v usloviiakh gemodializa.